Yervoy, Local Injection of Candidate Therapy Tilsotolimod Shrink Advanced Melanoma Tumors, Trial Shows

Source: Immuno-Oncology News, December 2018

A combination of Yervoy (ipilimumab) and Idera Pharmaceuticals’ investigational tilsotolimod reduced tumors in four out of 10 advanced melanoma patients included in a Phase 1/2 trial.

Findings from the ILLUMINATE-204 trial (NCT02644967) were presented at the European Society for Medical Oncology (ESMO) 2018 Congress, Oct. 19-23 in Munich, Germany. The poster was titled “Intratumoral (IT) Injection of the TLR9 agonist tilsotolimod (IMO-2125) in combination with ipilimumab (ipi) triggers durable responses in PD-1 inhibitor refractory metastatic melanoma (rMM): Results from a multicenter, phase I/II study.”

Tilsotolimod (previously known as IMO-2125) is designed to promote a broad activation of the immune system. The investigational therapy activates the Toll-like receptor 9 (TLR9), a protein found in certain immune cells, resulting in greater recognition and killing of tumor cells by the immune system.